We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo Announces Availability of RD SedLine Brain Sensors
Read MoreHide Full Article
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently announced the availability of the RD SedLine EEG sensor, which can be used with the company’s flagship SedLine Brain Function Monitoring technology. In fact, RD SedLine sensor is compatible for simultaneous use with the Masimo O3 Regional Oximetry platform. We note that an EEG or electroencephalogram is a test to find problems in the electrical activity of the brain.
The RD SedLine EEG sensor has exclusive features that provide clinicians with precise information about the brain. The sensor’s streamlined shape is user friendly and is expected to buoy patient satisfaction.
A glimpse of the price trend of the company reveals that the stock has had an impressive run on the bourse over the last six months. Masimo added 56%, comparing favorably with the Zacks classified Medical Instruments sub-industry’s decline of 2.1%. Also, the current level compares favorably with the S&P 500’s return of 6.9% over the same time frame.
Of the other positives, estimate revision for the stock has been solid. The full year has seen four analysts move north over the last one month, with one movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year increased 6% to $2.31 over the same time frame. Notably, the stock has Zacks Rank #2 (Buy).
Per management, the addition of RD SedLine EEG sensor should prove to be a great move for long-term growth of the company as it addresses both clinicians and patients.
The company has been gaining prominence in the niche markets with its wide portfolio that includes a few highly exclusive sensors. In this regard, last December, Masimo announced that its TFA-1 Single-Patient-Use Adhesive Forehead Sensor had received a 5I0(k) clearance from the U.S. FDA. The sensor examines a patient’s forehead using Masimo’s flagship SET Measure-through Motion and Low Perfusion pulse oximetry.
Our Take
Considering the bountiful opportunities for brain sensors and monitoring in the global market, the latest development instills investor confidence on the stock. A research report by Markets And Markets reveals that niche markets are expected to reach a worth of $12.22 billion globally by 2021, multiplying at a CAGR of 6.8%.
Additionally, Masimo’s long-term growth fundamentals are strong. The company recorded a five-year CAGR of 8.5% for revenues. The stock has particularly seen an improvement in earnings over the last three years.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% in the last quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Masimo Announces Availability of RD SedLine Brain Sensors
Irvine, CA-based Masimo Corporation (MASI - Free Report) recently announced the availability of the RD SedLine EEG sensor, which can be used with the company’s flagship SedLine Brain Function Monitoring technology. In fact, RD SedLine sensor is compatible for simultaneous use with the Masimo O3 Regional Oximetry platform. We note that an EEG or electroencephalogram is a test to find problems in the electrical activity of the brain.
The RD SedLine EEG sensor has exclusive features that provide clinicians with precise information about the brain. The sensor’s streamlined shape is user friendly and is expected to buoy patient satisfaction.
A glimpse of the price trend of the company reveals that the stock has had an impressive run on the bourse over the last six months. Masimo added 56%, comparing favorably with the Zacks classified Medical Instruments sub-industry’s decline of 2.1%. Also, the current level compares favorably with the S&P 500’s return of 6.9% over the same time frame.
Of the other positives, estimate revision for the stock has been solid. The full year has seen four analysts move north over the last one month, with one movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year increased 6% to $2.31 over the same time frame. Notably, the stock has Zacks Rank #2 (Buy).
Per management, the addition of RD SedLine EEG sensor should prove to be a great move for long-term growth of the company as it addresses both clinicians and patients.
The company has been gaining prominence in the niche markets with its wide portfolio that includes a few highly exclusive sensors. In this regard, last December, Masimo announced that its TFA-1 Single-Patient-Use Adhesive Forehead Sensor had received a 5I0(k) clearance from the U.S. FDA. The sensor examines a patient’s forehead using Masimo’s flagship SET Measure-through Motion and Low Perfusion pulse oximetry.
Our Take
Considering the bountiful opportunities for brain sensors and monitoring in the global market, the latest development instills investor confidence on the stock. A research report by Markets And Markets reveals that niche markets are expected to reach a worth of $12.22 billion globally by 2021, multiplying at a CAGR of 6.8%.
Masimo Corporation Price
Masimo Corporation Price | Masimo Corporation Quote
Additionally, Masimo’s long-term growth fundamentals are strong. The company recorded a five-year CAGR of 8.5% for revenues. The stock has particularly seen an improvement in earnings over the last three years.
Other Stocks to Consider
Other favorably ranked stocks in the broader medical sector include IDEXX Laboratories, Inc. (IDXX - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks (Strong Buy) here.
IDEXX Laboratories has a long-term expected earnings growth rate of approximately 15.04%. Notably, the stock represents an impressive one-year return of 90.6%.
Avinger projects sales growth of 30.7% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. Additionally, the company posted a positive earnings surprise of 1.6% in the last quarter.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>